Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia.
Goemans
B F
BF
Zwaan
C M
CM
Vijverberg
S J H
SJ
Loonen
A H
AH
Creutzig
U
U
Hählen
K
K
Reinhardt
D
D
Gibson
B E S
BE
Cloos
J
J
Kaspers
G J L
GJ
D000617:Aminoglycosides / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002648:Child; D019008:Drug Resistance, Neoplasm; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy* / Q000473:pathology*; D008297:Male; D014407:Tumor Cells, Cultured
D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000079982:Gemtuzumab